Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
PIPELINE
BUSINESS PARTNERSHIPS
Product Out-Licensing Co-Development
investor
Career development
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Our Story

Share the latest information

Our Story
News
Company News
Media
2025-05-13
Novamab to Present Phase IIa Clinical Trial Data of LQ036 at ATS 2025
More
2023-05-12
Novamab will present the latest progress of its promising products at ATS 2023 and BIO International Convention 2023
More
2023-04-06
Novamab:Systematic Opportunities for Antibody Inhalation Administration
More
2023-01-06
The clinical trial of Novamab's inhaled TSLP nanoantibody drug LQ043H was approved by CDE
More
2022-11-30
LQ036, the world's first inhaled sdAb drug for the treatment of moderate and severe asthma, has completed the administration of the first patient in China's clinical phase I!
More
2022-11-29
The research results of Novamab long-acting IL-5 nanoantibody were published in Research Research!
More
2022-11-11
Exclusive interview with Dr. Wan Yakun: the fifth anniversary of Novamab, the next goal is Ablynx
More
2022-11-02
Wan Yakun of Novamab: Dream of Zhangjiang Science City, and brave the difficulties of nanoantibody pharmaceutical
More
2022-10-17
Novamab | Five years of joint efforts to start a new journey
More
2022-09-27
Novamab won the support of Shanghai's 2022 annual innovation fund plan
More
2022-09-16
Novamab was listed in "Top 100 Chinese pharmaceutical innovative seed enterprises in 2022"
More
总计 53 123456